
## Marco Macagno

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3233279/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. Biomedicines, 2022, 10, 230.	3.2	1
2	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	9.4	48
3	True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer Letters, 2021, 507, 89-96.	7.2	10
4	Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients. Cancers, 2020, 12, 3633.	3.7	7
5	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1017-1024.	7.0	22
6	NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Annals of Translational Medicine, 2019, 7, 105-105.	1.7	143
7	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody. Clinical Cancer Research, 2018, 24, 3377-3385.	7.0	31
8	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. Clinical Cancer Research, 2017, 23, 2277-2288.	7.0	34
9	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. Oncolmmunology, 2016, 5, e1253653.	4.6	30
10	Immunotargeting of Antigen xCT Attenuates Stem-like Cell Behavior and Metastatic Progression in Breast Cancer. Cancer Research, 2016, 76, 62-72.	0.9	93
11	A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model. Oncotarget, 2016, 7, 33081-33095.	1.8	15
12	Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice. BioMed Research International, 2014, 2014, 1-16.	1.9	22
13	Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. Journal of Immunology, 2014, 192, 5434-5441.	0.8	16
14	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. Current Topics in Microbiology and Immunology, 2014, 405, 99-122.	1.1	10
15	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. Oncolmmunology, 2013, 2, e26137.	4.6	27
16	Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. Cancers, 2011, 3, 3225-3241.	3.7	21